 |
Bergamo |
|
Bergamo |
Nephrology, Dialysis
and Transplantation Unit, Ospedali Riuniti di Bergamo
and
Mario Negri Institute for Pharmacological Research, Bergamo,
Italy
The Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo is formally associated in a public-private partnership with the Mario Negri Institute for Pharmacological Research, Bergamo, and the two partners share common interests and research projects in the filed of kidney diseases.
Peer Reviewed Publications in International Journals (only English) 2000-2003
PUBLICATIONS LIST 2000-2003 (until July 31, 2003)
| 1. |
P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathies including hemolytic uremic syndrome. In: Comprehensive Clinical Nephrology, Chapter n. 33, Section 5: Glomerular Disease, edited by Johnson RJ, Feehally J., Mosby, London pp. 33.1-33.12, 2000. |
| 2. | P. Ruggenenti, A. Perna, C. Zoccali, G. Gherardi, R. Benini, A. Testa, G. Remuzzi for the (GISEN). Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 2000;11:88-96. |
| 3. | G. Remuzzi, L. Minetti. Hematological consequences of renal failure. In: Brenner and Rector's The Kidney, 6° ed., Vol. II, chapter n. 50, edited by Brenner BM, W.B. Saunders Company, Philadelphia, pp. 2079-2102, 2000. |
| 4. |
D. Macconi, M. Ghilardi, M.E.Bonassi, E.I.Mohamed, M.Abbate, F. Colombi, G. Remuzzi, A. Remuzzi. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000;11:477-489. |
| 5 | P. Ruggenenti, L. Mosconi, G. Vendramin, M. Moriggi, A. Remuzzi, F. Sangalli, G. Remuzzi. ACE inhibition improves glomerular size-selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 2000;35:381-391. |
| 6. |
P. Ruggenenti, G. Remuzzi. The role of protein traffic in the progression of renal diseases. Annu Rev Med 2000;51:315-327. |
| 7. | S. Tomasoni, N. Azzollini, F. Casiraghi, M.C. Capogrossi, G. Remuzzi, A. Benigni. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol 2000;11:747-752. |
| 8. | A. Perna, P. Ruggenenti, A. Testa, B. Spoto, R. Benini, V. Misefari, G. Remuzzi, C. Zoccali for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000;57:274-281. |
| 9. |
A. Benigni, G. Remuzzi. Prostacyclin and thromboxane and the development of preeclampsia. Letter. JAMA 2000;283:1568-1569. |
| 10. | MacLeod JM, White KE, Tate H, Bilous RW, on behalf of the ESPRIT Study Group (P. Ruggenenti, F. Gaspari, G. Remuzzi). Measurement of glomerular volume in needle biopsy specimens. Nephrol Dial Transplant 2000;15:239-243 |
| 11. | G. Remuzzi. Effect of cigarette smoking on renal function and vascular endothelium. In: Cigarette Smoking and the Kidney. Contrib Nephrol. Edited by Sessa A, Conte F, Meroni M, Battini G. Basel, Karger, vol.130:45-52. |
| 12. | S. Aiello, M. Noris, G. Piccinini, S. Tomasoni, F. Casiraghi, S. Bonazzola, M. Mister, M.H. Sayegh, G. Remuzzi. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. J Immunol 2000;164:4649-4658. |
| 13. | P. Ruggenenti, A. Perna, G. Gherardi, R. Benini, G. Remuzzi. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-1165. |
| 14. | G. Dotti, R. Fiocchi, T. Motta, A. Gamba, E. Gotti, B. Gridelli, G. Borleri, C. Manzoni, P. Viero, G. Remuzzi, T. Barbui, A. Rambaldi. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-833. |
| 15. | R. Pisoni, G. Remuzzi. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? J Nephrol 2000;13:228-231. |
| 16. | G. Remuzzi, P. Ruggenenti. Renal transplantation: single or dual for donors aging = 60 years? Analyses & Commentaries. Transplantation 2000;69:2000-2004. |
| 17. |
B. Gridelli, G. Remuzzi. Strategies for making more organs available for transplantation. N Engl J Med 2000;343:404-410. |
| 18. | R. Pisoni, G. Remuzzi. Thrombotic microangiopathy. Eur J Int Med 2000;11:135-139. |
| 19. | B. Imberti, M. Morigi, C. Zoja, S. Angioletti, M. Abbate, A. Remuzzi, G. Remuzzi. Shear stress-induced cytoskeleton rearrangement mediates NF-kB dependent endothelial expression of ICAM-1. Microvasc Res 2000;60:182-188. |
| 20. | A. Benigni, S. Tomasoni, J. Lutz, S. Amuchastegui, M.C. Capogrossi, G. Remuzzi. Nonviral and viral gene transfer to the kidney in the context of transplantation. Nephron 2000;85:307-316. |
| 21. | A. Benigni, N. Perico, G. Remuzzi. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol 2000;35 (Suppl.2):S75-S78. |
| 22. | G. Remuzzi. A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. Nephrol Dial Transplant 2000;15 (Suppl.6):58-60. |
| 23. | G. Remuzzi. Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. Int J Clin Practice 2000;Suppl. 110:9-15. |
| 24. | P. Ruggenenti, G. Remuzzi. Nephropathy of type1 and type 2 diabetes: diverse pathophysiology, same treatment? Editorial Comments. Nephrol Dial Transplant 2000;15:1900-1902. |
| 25. | P. Ruggenenti, A. Perna, M. Lesti, R. Pisoni, L. Mosconi, F. Arnoldi, I. Ciocca, F. Gaspari, G. Remuzzi. Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Kidney Int 2000;58:2093-2101. |
| 26. | G. Remuzzi, B. Gridelli. Organs for transplantation. Correspondence. N Engl J Med 2000;343:1730-1732. |
| 27. | L.Naldi, A.Belloni Fortina, S. Lovati, A. Barba, E. Gotti, G. Tessari, D. Schena, A. Diociaiuti, G. Nanni, I. Lesnoni La Parola, C. Masini, S. Piaserico, A. Peserico, T. Cainelli, G. Remuzzi. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000;70:1479-1484. |
| 28. | G. Remuzzi. Hemolytic uremic syndrome: past and present. Am J Kidney Dis 2000;36:liv-lvi. |
| 29. | M. Noris, M. Todeschini, S. Zappella, S. Bonazzola, C.Zoja, D. Corna, F. Gaspari, F. Marchetti, S. Aiello, G. Remuzzi. 17b-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. Am J Physiol: Renal Physiology 2000;279:F626-F635. |
| 30. | M. Galbusera, A. Remuzzi, A. Benigni, C. Rossi, G. Remuzzi. A novel interpretation of the role of von Willebrand Factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. Am J Kidney Dis 2000;36:695-702. |
| 31. | P. Ruggenenti, G. Remuzzi. Treatment of adult hemolytic-uremic syndrome. Advances in Nephrology 2000;30:83-94. |
| 32. | G. Remuzzi, A. Benigni. Repairing renal lesions: Will VEGF be the builder? Kidney Int 2000;58:2594-2595 (Editorial). |
| 33. | G. Remuzzi, N. Perico, E. Gotti, P. Ruggenenti, G. Rota, G. Locatelli. The kidney transplant program at the Bergamo Center, edited by Cecka and Terasaki. Clinical Transplants, chapter 15, UCLA Immunogenetics Center, Los Angeles, California, pp. 179-191, 2000. |
| 34. | B.M. Brenner, M.E. Cooper, D. de Zeeuw, J-P Grunfeld, W.F. Keane, K. Kurokawa, J.B. McGill, W.E. Mitch, H.H. Parving, G. Remuzzi, A.B. Ribeiro, M.D. Schluchter, D. Snavely, Z. Zhang, R. Simpson, D. Ramjit, S. Shahinfar, for the RENAAL Study Investigators. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of endpoints in NIDDM with the angiotensin II antagonist losartan). J Renin-Angiotensin-Aldosterone System 2000;1:328-335. |
| 35. | R. Donadelli, M. Abbate, C. Zanchi, D. Corna, S. Tomasoni, A. Benigni, G. Remuzzi, C. Zoja. Protein traffic activates NF-kB gene signaling and promotes MCP-1 dependent interstitial inflammation. Am J Kidney Dis 2000;36:1226-1241. |
| 36. | Blood Pressure Lowering Treatment Trialists' Collaboration (G. Remuzzi, P. Ruggenenti). Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-1964. |
| 37. | M. Noris, J. Caprioli, G. Remuzzi. Pathophysiology of thrombotic microangiopathies. Int Med 2000;8:37-43. |
| 38. | A. Benigni, N. Perico, G. Remuzzi. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Special commentary. Curr Opin Nephrol Hypertens 2001;10:1-6. |
| 39. | J. Caprioli, P. Bettinaglio, P.F. Zipfel, B. Amadei, E. Daina, S. Gamba, C. Skerka, N. Marziliano, G. Remuzzi, M. Noris on behalf of the Italian Registry of Familial and Recurrent HUS/TTP. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001;12:297-307. |
| 40. | P. Ruggenenti, E. Pagano, L. Tammuzzo, R. Benini, L. Garattini, G. Remuzzi, on behalf of the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001;59:286-294. |
| 41. | G. Dotti, F. Gaspari, R. Caruso, N. Perico, G. Remuzzi, T. Barbui, A. Rambaldi. Pharmacokinetic study of the new cyclosporin-A formulation (NeoralTM) in adult allogeneic bone marrow transplant recipients. Haematologica 2001;86:311-315. |
| 42. | C. Zoja, P. Ruggenenti, G. Remuzzi. Role of coagulation in glomerular and vascular diseases. Part 1. In: Textbook of Nephrology, 4° ed, chapter n. 37, edited by Massry SG, Glassock RJ. Lippincott Williams & Wilkins, Philadelphia, pp. 589-594, 2001. |
| 43. | P. Boccardo, G. Remuzzi. Bleeding and coagulation. Part. 2. In: Textbook of Nephrology, 4° ed, chapter n. 72, edited by Massry SG, Glassock RJ. Lippincott Williams & Wilkins, Philadelphia, pp.1324-1329, 2001. |
| 44. | M. Abbate, G. Remuzzi. Mechanisms. Part. 2. In: Textbook of Nephrology, 4° ed, chapter n. 67, edited by Massry SG, Glassock RJ. Lippincott Williams & Wilkins, Philadelphia, pp.1210-1217, 2001. |
| 45. | R. Pisoni, G. Remuzzi. Pathophysiology and management of progressive chronic renal failure. In: 'Primer on Kidney Diseases', National Kidney Foundation. 3rd ed, chapter n.58, edited by Arthur Greenberg, Academic Press, San Diego, California, pp. 385-396, 2001. |
| 46. | P. Ruggenenti, A. Schieppati, G. Remuzzi. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608. |
| 47. | P. Ruggenenti, G. Remuzzi. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. In: 'Nephrology', Clinical Medicine Series. Chapter n. 36, edited by Francesco P. Schena, McGraw-Hill International, Berkshire,England, pp. 361-370, 2001. |
| 48. | The European Study for the Prevention of Renal disease in Type 1 diabetes (ESPRIT) P. Ruggenenti, F. Gaspari, G. Remuzzi. Effect of three years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. Diabetes 2001; 50:843-850. |
| 49. | P. Ruggenenti, C. Aros, G. Remuzzi. Thrombotic microangiopathies in the intensive care unit: many questions, some answers. In: Blood Purification in Intensive Care. Contrib Nephrol, edited by C. Ronco, R. Bellomo. Basel, Karger, 2001;132:53-67. |
| 50. | A. Benigni, G. Remuzzi. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001;37(1 Suppl 2):S21-S24 |
| 51. | A. Benigni, S. Tomasoni, E. Gagliardini, C. Zoja, J.A. Grunkemeyer, R. Kalluri, G. Remuzzi. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-948. |
| 52. | R. Pisoni, P. Ruggenenti, G. Remuzzi. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Safety 2001;24(7):491-501 |
| 53. | P.F. Zipfel, C. Skerka, J. Caprioli, T. Manuelian, H. H. Neumann, M. Noris, G. Remuzzi. Complement factor H and hemolytic uremic syndrome. International Immunopharmacology 2001;1:461-468. |
| 54. | M. Abbate, G. Remuzzi. Novel mechanism(s) implicated in tubular albumin reabsorption and handling. (J Club Discussion) Am J Kidney Dis 2001;38 (1):196-204. |
| 55. | P. Ruggenenti, B.M. Brenner, G. Remuzzi. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001;88:254-259. |
| 56. | T.H. Jafar, C.H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes. Ann Intern Med 2001;135 (2):S-21. |
| 57. | T.H. Jafar, C.H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001;135 (2):73-87. |
| 58. | P. Ruggenenti, L. Mosconi, S. Bruno, A. Remuzzi, F. Sangalli, M.S. Lepre, R. Agazzi, R. Nani, G. Fasolini, G. Remuzzi. Post-transplant renal artery stenosis: the hemodynamic response to revascularization. Kidney Int 2001;60:309-318. |
| 59. | B. Ene-Iordache, L. Mosconi, G. Remuzzi, A. Remuzzi. Computational fluid dynamics of a vascular access case for hemodialysis. J Biomech Eng 2001;123:284-292. |
| 60. | R. Pisoni, P. Ruggenenti, G. Remuzzi. Renoprotective therapy in patients with non-diabetic nephropathies. Drugs 2001;61 (6):733-745. |
| 61. | C. Zoja, A. Benigni, M. Noris, D.Corna, F. Casiraghi, M. Pagnoncelli, D. Rottoli, M. Abbate, G. Remuzzi. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis and prolongs animal life. Kidney Int 2001;60:653-663. |
| 62. | M. Morigi, M. Galbusera, E. Binda, B. Imberti, S.Gastoldi, A. Remuzzi, C. Zoja, G. Remuzzi. Verotoxin-1-induced upregulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001;98(6):1828-1835. |
| 63. | P. Ruggenenti, M. Noris, G. Remuzzi. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846. |
| 64. | P. Boccardo, M. Noris, G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: Dialysis Therapy, 3rd edition. Edited by Nissenson A.R., Fine R.N. Hanley & Belfus, Inc., Philadelphia 2001;3:190-194. |
| 65. | F. Gaspari, N. Perico, G. Remuzzi. Pharmacologic monitoring of immunosuppressive drugs. Current & Future Immunosuppressive Therapies Following Transplantation. Edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publisher, The Netherlands 2001;1:317-334. |
| 66. | T.H. Jafar, P.C. Stark, C.H. Schmid. M. Landa, G. Maschio, C. Marcantoni, P.E. de Jong, D. de Zeeuw, S. Shahinfar, P. Ruggenenti, G. Remuzzi, A.S. Levey. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140. |
| 67. | A. Benigni, N. Perico, G. Remuzzi. Molecular medicine in organ transplantation: how and when? Current & Future Immunosuppressive Therapies Following Transplantation. Edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publisher, The Netherlands 2001;1:317-334. |
| 68. | B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H-H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-869. |
| 69. | A.D. Salama, G. Remuzzi, W.E. Harmon, M.H. Sayegh. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001;108(7):943-948. |
| 70. | A. Schieppati, G. Remuzzi. The uses of error: diagnostic preferences. The Lancet 2001;358:1005. |
| 71. | M. Noris, N. Azzollini, A. Pezzotta, M. Mister, A. Benigni, G. Marchetti, E. Gagliardini, N. Perico, G. Remuzzi. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001;12:1937-1946. |
| 72. | R. Caruso, N. Perico, D. Cattaneo, G. Piccinini, S. Bonazzola, G. Remuzzi, F. Gaspari. Whole blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clinical Chemistry 2001;47(9):1679-1687. |
| 73. | M. Noris, G. Remuzzi. Familial and recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Rare Kidney Diseases.Contrib Nephrol. Edited by A. Schieppati, E. Daina, A. Sessa, G. Remuzzi. Basel, Karger 2001;136:125-139. |
| 74. | S. Tomasoni, G. Remuzzi, A. Benigni. Gene therapy to the kidney. Rare Kidney Diseases.Contrib Nephrol. Edited by A. Schieppati, E. Daina, A. Sessa, G. Remuzzi. Basel, Karger 2001;136:140-156. |
| 75. | P. Ruggenenti, C. Aros, G. Remuzzi. Renin-Angiotensin System, proteinuria and tubulointerstitial damage. The Renin-Angiotensin System and Progression of Renal Diseases. Contrib Nephrol. Edited by Wolf, G. Basel, Karger 2001;135:187-199. |
| 76. | L. Antiga, B. Ene-Iordache, G. Remuzzi, A. Remuzzi. Automatic generation of glomerular capillary topological organization. Microvasc Res 2001;62:346-354. |
| 77. | A. Schieppati, G. Remuzzi, S. Garattini. Modulating the profit motive to meet needs of the lesss-developed world. Lancet 2001;358:1638-1641. |
| 78. | A. Benigni, E. Gagliardini, A. Remuzzi, D. Corna, G. Remuzzi. ACE inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. Am J Pathol 2001;159:1743-1750. |
| 79. | M. Jonker, Y. van den Hout, R.C. Noort, M.F.J. Versteeg-van der Voort Maarschalk, F.H.J. Claas, F.J. vd Woude, D. Hollander, N. Perico, G. Remuzzi. Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. Transplantation 2001;72:1432-1436. |
| 80. | G. Remuzzi, N. Perico. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hyperten 2002;11:1-10. |
| 81. | D. Cattaneo et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clinical Transpl 2001;15:402-409. |
| 82. | B. Gridelli, N. Perico, G. Remuzzi. Scarsa disponibilità di organi: strategie di adattamento. Scienza e Cultura nel Mondo. Edited by Duebi Nuove Frontiere. Roma 2001;2:7-14. |
| 83. | C. Zoja, M. Morigi, G. Remuzzi. The role of the endothelium in hemolytic uremic syndrome. J Nephrol 2001;14 Suppl. 4:S58-62. |
| 84. | F. Gaspari, R. Caruso, D. Cattaneo, N. Perico, G. Remuzzi. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? Transplant Proc 2001;33:3117-3119. |
| 85. | N. Perico, A. Benigni, G. Remuzzzi. Xenotransplantation in the 21st century. Blood Purification 2002; 20:45-54. |
| 86. | R. Plata, A. Cornejo, C. Arratia, A. Anabaya, A. Perna, B. Dimitrov, G. Remuzzi, P. Ruggenenti for the Commission on Global Advancement of Nephrology (COMGAN). Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomized trial. Lancet 2002;359:663-666. |
| 87. | B.D. Dimitrov, G. Remuzzi. Combination therapy for renal disease. Hospital Prescriber Europe 2002;3:21-23. |
| 88. |
M. Noris, D. Cugini, F. Casiraghi, N. Azzollini, L. De Deus Viera Moraes, M. Mister, A. Pezzotta, R. Aparecida Cavinato, S. Aiello, N. Perico, G. Remuzzi. Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. J Am Soc Nephrol 2001;12:2815-2826. |
| 89. | C. Zoja, M. Morigi, G. Remuzzi. Coagulation and thrombosis in immunologic renal diseases. In: Immunologic Renal Diseases: Edited by E.G. Neilson, W.G. Couser, Lippincott Williams & Wilkins Publishers, Philadelphia, pp.511-520, 2001. |
| 90. | P. Ruggenenti, M. Galli, G. Remuzzi. Hemolytic uremic syndrome, Thrombotic thrombocytopenic purpura, and antiphospholipid antibody syndromes. In: Immunologic Renal Diseases: Edited by E.G. Neilson, W.G. Couser, Lippincott Williams & Wilkins Publishers, Philadelphia, pp.1173-1201, 2001. |
| 91. | M. Mister, M. Noris, J. Szymczuk, N. Azzollini, S. Aiello, M. Abbate, L. Trochimowicz, E. Gagliardini, A. Arduini, N. Perico, G. Remuzzi. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 2002;61:1064-1078. |
| 92. | P. Ruggenenti, A. Perna, G. Remuzzi. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a Post Hoc analysis of the REIN trial results. J Am Soc Nephrol 2002;12:2832-2837. |
| 93. | G. Remuzzi, P. Ruggenenti, N. Perico. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615. |
| 94. | N. Perico, G. Remuzzi. Nitric oxide and renal perfusion in humans. J Hypertens 2002;20:391-393. |
| 95. | M. Noris, G. Remuzzi. ACE inhibitors and AT1 receptor antagonists: Is two better than one? Kidney Int 2002;61:1545-1547. |
| 96. | A. Benigni, S. Tomasoni, G. Remuzzi. Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. Kidney Int 2002;61 (Symposium 1):S115-S119. |
| 97. | G. Remuzzi, A. Schieppati, P. Ruggenenti. Clinical Practice: Nephropathy in patients with type 2 diabetes. New Engl J Med 2002;346:1145-1151. |
| 98. | C. Zoja, D. Corna, D. Rottoli, D. Cattaneo, C. Zanchi, S. Tomasoni, M. Abbate, G. Remuzzi. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635-1645. |
| 99. | G. Remuzzi, P. Ruggenenti, D. Codazzi, M. Noris, J. Caprioli, G. Locatelli, B. Gridelli. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002;359:1671-1672. |
| 100. | C. Chiurchiu, P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathy in renal transplantation. Annals of Transpl 2002;7:28-33. |
| 101. | C. Aros, G. Remuzzi. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002;20(3):S45-S53. |
| 102. | M. Abbate, C. Zoja, D. Rottoli, D. Corna, S. Tomasoni, G. Remuzzi. Proximal tubular cells promote fibrogenesis by TGF-b1-mediated induction of peritubular myofibroblasts. Kidney int 2002;61:2066-2077. |
| 103. | M. Morigi, D. Macconi, C. Zoja, R. Donadelli, S. Buelli, C. Zanchi, M. Ghilardi, G. Remuzzi. Protein overload-induced NF-kB activation in proximal tubular cells requires H2O2 through a PKC-dependent pathway. J Am Soc Nephrol 2002;13:1179-1189. |
| 104. | G. Remuzzi, M. Galbusera, M. Noris, M.T. Canciani, E. Daina, E. Bresin, S. Contaretti, J. Caprioli, S. Gamba. Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002;100:778-785. |
| 105. | D. Cattaneo, N. Perico, F. Gaspari, E. Gotti, G. Remuzzi. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002;62:1060-1067. |
| 106. | R.C. Campbell, G. Remuzzi. Halting the progression of renal disease: where we stand? Editorial. Nefrologia 2002;XXII(4):303-305. |
| 107. | A. Schieppati, N. Perico, G. Remuzzi. Tacrolimus and ciclosporin microemulsion in renal transplantation. Correspondence. Lancet 2002;360:799-800. |
| 108. | G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, P. Ruggenenti. Rituximab for idiopathic membranous nephropathy. Research Letter. Lancet 2002;360:923-924 |
| 109. | R. Pisoni, R. Faraone, P. Ruggenenti, G. Remuzzi. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J Nephrol 2002;15:428-430. |
| 110. | C. Zoja, S. Angioletti, R. Donadelli, C. Zanchi, S. Tomasoni, E. Binda, B. Imberti, M. te Loo, L. Monnens, G. Remuzzi, M. Morigi. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002;62:846-856. |
| 111. | A. Remuzzi, E. Gagliardini, C. Donadoni, A. Fassi, F. Sangalli, M.S. Lepre, G. Remuzzi, A. Benigni. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-894. |
| 112. | R. Pisoni, P. Ruggenenti, F. Sangalli, M.S. Lepre, A. Remuzzi, G. Remuzzi. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 2002;62:1010-1019. |
| 113. | A. Schieppati, N. Perico, G. Remuzzi. Conflict of interest as seen from a researcher's perspective. Science and Engineering Ethics 2002;8:337-342. |
| 114. | R. Pisoni, C. Aros, P. Ruggenenti, G. Remuzzi. Mechanisms of progression of chronic renal disease. Saudi J Kidney Dis Transplant 2002;13:250-256. |
| 115. | B. Ene-Iordache, S. Bruno, A. Remuzzi, G. Remuzzi. Effect of hemodynamic conditions on arteriovenous fistula for hemodialysis access. Hemodialysis Technology. Contrib Nephrol. Edited by C. Ronco,and G. La Greca. Basel, Karger 2002;137:54-59. |
| 116. | P. Bettinaglio, A. Galbusera, J. Caprioli, S. Orisio, A. Perna, F. Arnoldi, S. Bucchioni, M. Noris on behalf of the BENEDICT Study Group. Single Strand Conformation Polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. Clinical Biochemistry 2002;35:363-368. |
| 117. | M. Todeschini, D. Macconi, N. Garcia Fernandez, M. Ghilardi, A. Anabaya, E. Binda, M. Morigi, D. Cattaneo, E. Perticucci, G. Remuzzi, M. Noris. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis 2002;40:783-793. |
| 118. | G. Remuzzi, N. Perico, A. Benigni. New therapeutics that antagonize endothelin: promises and frustrations. Nature Reviews Drug Discovery 2002;1:986-1001. |
| 119. | W.C. Gerth, G. Remuzzi, G. Viberti, T. Hannedouche, A. Martinez-Castelao, S. Shahinfar, G.W. Carides, B. Brenner. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002;62:S68-S72. |
| 120. | R.C. Campbell, P. Ruggenenti, G. Remuzzi. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002;13:S190-S195. |
| 121. | N. Perico, P. Ruggenenti, M. Scalamogna, G. Locatelli, G. Remuzzi. One or two marginal organs for kidney transplantation? Transplant Proc 2002;34:3091-3096. |
| 122. | M. Abbate, C. Zoja, M. Morigi, D. Rottoli, S. Angioletti, S. Tomasoni, C. Zanchi, L. Longaretti, R. Donadelli, G. Remuzzi. Transforming Growth Factor-b1 is upregulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002;161:2179-2193. |
| 123. | C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, G. Remuzzi. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-2908 |
| 124. | M. Abbate, G. Remuzzi. Renoprotection: Clues from knockout models of rare disease. Kidney Int 2003;63:764-766. |
| 125. | R. Campbell, F. Sangalli, E. Perticucci, C. Aros, C. Viscarra, A. Perna, A. Remuzzi, F. Bertocchi, L. Fagiani, G. Remuzzi, P. Ruggenenti. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-1103. |
| 126. | B.D. Dimitrov, A. Perna, P. Ruggenenti, G. Remuzzi. Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney Int 2003;63:1924-1933. |
| 127. | C. Chiurchiu, A. Firrincieli, M. Santostefano, M. Fusaroli, G. Remuzzi, P. Ruggenenti. Adult non-diarrhea hemolytic uremic syndrome associated with shiga toxin Escherichia coli 0157:H7 bacteremia and urinary tract infection. Am J Kidney Dis 2003;41:E4. |
| 128. | P. Ruggenenti, N. Mise, R. Pisoni, F. Arnoldi, A. Pezzotta, A. Perna, D. Cattaneo, G. Remuzzi. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003;107:586-592. |
| 129. | A. Schieppati, N. Perico, G. Remuzzi. Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Kidney Int 2003;63:1948-1950. |
| 130. | E. Gotti, N. Perico, A. Perna, F. Gaspari, D. Cattaneo, R. Caruso, S. Ferrari, N. Stucchi, G. Marchetti, M. Abbate, G. Remuzzi. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 2003;14:755-766. |
| 131. | P. Ruggenenti, A. Perna, G. Remuzzi on behalf of the Investigators of the GISEN Group. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003;63:2254-2261. |
| Books | |
| 1. | Hemostasis, Prostaglandins and Renal Disease, edited by Remuzzi G., Mecca G., de Gaetano G., Raven Press, New York 1980 |
| 2. | Glomerular injury: 300 years after Morgagni, edited by Bertani T., Remuzzi G., Wichtig Editore, Milano 1983 |
| 3. | Drugs and Kidney, edited by Bertani T., Remuzzi G., Garattini S., Raven Press, New York 1986 |
| 4. | Haemostasis and the Kidney, edited by Remuzzi G., Rossi E.C., Butterworths, London 1989 |
| 5. | Current & Future Immunosuppressive Therapies Following Transplantation, edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publishers, The Netherlands 2001 |
| 6. | Rare Kidney Disease, edited by Schieppati A., Daina E., Sessa A., Remuzzi G., Karger, Basel 2001 |
